department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Hemlibra · pharmadog

pharmadog
drugs
Hemlibra

drug · antibody

patient view →

emicizumab

Phase 2updated 2mo ago

by Chugai Pharmaceutical Co Ltd🔗 ChEMBL

Phase 2

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

targets

Coagulation factor IX and X

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Hemlibra

trade names

Hemlibra

generic

emicizumab-kxwh

MOA

Coagulation factor IX and X other

indication

Acquired Hemophilia A

phase

phase_2

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying emicizumab

phase3A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Diseaserecruitingn=75
phase3A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia Arecruitingn=360
phase4A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxisactive not recruitingn=136
phase3A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitorsactive not recruitingn=55
phase1Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia Arecruitingn=40
phase3Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participantscompletedn=85
phase3SAFE Study: Safety of aPCC Following Emicizumab Prophylaxisrecruitingn=5
phase3A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitorscompletedn=73

more trials →